Rheumatoid Arthritis Drugs Market Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast To 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch. Highlights Key Questions Answered - How large an impact will biosimilars have on the RA market? What do rheumatologists and key opinion leaders across the 10MM think about the evolving RA treatment landscape? - How is the uptake of JAK inhibitors expected to affect the global RA market? - Which novel biologics are the most promising? How are product launches expected to affect the anti-TNFs? Browse full report on: http://www.radiantinsights.com/research/pharmapoint-rheumatoidarthritis-global-drug-forecast-and-market-analysis-to-2023 - According to KOLs, what are the most important unmet needs in RA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2023? - What governmental and industry developments are likely to affect sales of the top-selling RA drugs in the markets researched? Which is the largest growth market globally? Key Findings - Biosimilars are expected to change the landscape for RA and create pricing pressure in the RA market. However, questions from physicians and regulators regarding the appropriate use of biosimilars still lingers. - Sales of anti-TNFs are expected to decline due to the introduction of biosimilars and other novel biologics and small molecules to treat RA. - Developers of pipeline products will need strong clinical data and a clear development and commercialization strategy to penetrate the competitive RA market.
- The market will continue to be dominated by Big Pharma who will leverage their R&D, manufacturing, and distribution networks. Scope - Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and countryspecific diagnosis and treatment recommendations. - Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the RA biologics and biosimilars markets. - Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte's baricitinib), novel biologics (such as AstraZeneca-MedImmune's mavrilimumab), and biosimilars (such as Celltrion/Hospira/Alvogen's Inflectra/Remsima). - Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare Reasons To Buy - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the RA market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global RA market from 2013-2023. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Table Of Content: Table of Contents 10 1.1 List of Tables 17 1.2 List of Figures 25 2 Introduction 28 2.1 Catalyst 28 2.2 Related Reports 29
2.3 Upcoming Related Reports 29 3 Disease Overview 30 3.1 Etiology and Pathophysiology 30 3.1.1 Etiology 30 3.1.2 Pathophysiology 30 3.2 Symptoms 35 3.3 Prognosis 36 3.4 Quality of Life 36 4 Epidemiology 37 4.1 Disease Background 37 4.2 Risk Factors and Comorbidities 37 4.3 Global Trends 39 4.3.1 US 39 4.3.2 5EU 40 4.3.3 Japan 41 4.3.4 Australia 41 4.3.5 China 42 4.3.6 India 42 4.4 Forecast Methodology 42 4.4.1 Sources Used 45 To View sample pages click on: http://www.radiantinsights.com/research/pharmapointrheumatoid-arthritis-global-drug-forecast-and-market-analysis-to-2023#tabs-4 4.4.2 Sources Not Used 49 4.4.3 Forecast Assumptions and Methods - Total Prevalent Cases of RA 50 4.4.4 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of RA 54 4.5 Epidemiological Forecast for RA (2013-2023) 55 4.5.1 Total Prevalent Cases of RA 55 4.5.2 Age-Specific Total Prevalent Cases of RA 57 4.5.3 Sex-Specific Total Prevalent Cases of RA 59 4.5.4 Diagnosed Prevalent Cases of RA 61 4.5.5 Age-Standardized Diagnosed Prevalence of RA 63 4.6 Discussion 65 4.6.1 Epidemiological Forecast Insight 65 4.6.2 Limitations of the Analysis 65 4.6.3 Strengths of the Analysis 66 5 Disease Management 67 5.1 Diagnosis and Treatment Overview 67 5.1.1 Diagnosis 67 5.1.2 Treatment Guidelines 69 5.1.3 Leading Prescribed Drugs for the Treatment of RA 78
5.1.4 Clinical Practice 79 5.2 US 84 5.3 France 88 5.4 Germany 89 5.5 Italy 92 5.6 Spain 94 5.7 UK 95 5.8 Japan 99 5.9 Australia 101 5.10 China 103 5.11 India 105 6 Competitive Assessment 108 6.1 Overview 108 6.2 Product Profiles - Major Brands 109 6.2.1 Enbrel (etanercept) 109 6.2.2 Humira (adalimumab) 116 6.2.3 Remicade (infliximab) 120 6.2.4 Simponi (golimumab) 126 6.2.5 Cimzia (certolizumab pegol) 132 6.2.6 Orencia (abatacept) 136 6.2.7 Actemra/RoActemra (tocilizumab) 142 6.2.8 Rituxan/MabThera (rituximab) 150 6.2.9 Inflectra/Remsima (infliximab biosimilar) 155 6.2.10 Xeljanz (tofacitinib) 158 Enquire About Report: http://www.radiantinsights.com/research/pharmapointrheumatoid-arthritis-global-drug-forecast-and-market-analysis-to-2023 6.2.11 Iguratimod/T-614 165 6.2.12 Methotrexate (Numerous Brands) 169 6.3 Biosimilars 172 6.3.1 Introduction 172 6.3.2 Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases 174 6.3.3 Biosimilars in the Immunology Community 174 6.3.4 By the Numbers: Biosimilars in Development 175 6.3.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 179 6.3.6 Uptake of Biosimilars for RA is Expected to Vary by Market 180 6.3.7 Biosimilars' Forecast 183 6.4 Other Therapies 191 7 Unmet Need and Opportunity 193 7.1 Overview 193 7.2 Development of Cost-Effective Therapies 194 7.2.1 Unmet Need 194
7.2.2 Gap Analysis 195 7.2.3 Opportunity 195 7.3 Biomarkers to Predict Responsiveness to Therapy 196 7.3.1 Unmet Need 196 7.3.2 Gap Analysis 198 7.3.3 Opportunity 198 7.4 Early Diagnosis of RA 199 7.4.1 Unmet Need 199 7.4.2 Gap Analysis 200 7.4.3 Opportunity 201 7.5 Personalized Treatment Approach 202 7.5.1 Unmet Need 202 7.5.2 Gap Analysis 202 7.5.3 Opportunity 204 Request Free Sample Of This Study @ http://www.radiantinsights.com/research/pharmapoint-rheumatoid-arthritis-global-drugforecast-and-market-analysis-to-2023#tabs-4 8 Pipeline Assessment 206 8.1 Overview 206 8.2 Clinical Trial Mapping 206 8.2.1 Clinical Trials by Class 206 8.3 Promising Drugs in Clinical Development 208 8.3.1 Sarilumab 215 8.3.2 Sirukumab 223 8.3.3 Clazakizumab 230 8.3.4 Cosentyx (secukinumab) 236 8.3.5 Tregalizumab 242 8.3.6 Mavrilimumab 248 8.3.7 Denosumab (Prolia/Xgeva) 253 8.3.8 Baricitinib 259 8.3.9 Peficitinib 269 8.3.10 Decernotinib 275 8.3.11 Filgotinib 281 8.3.12 Masitinib 287 8.3.13 RAVAX 294 8.4 Other Drugs in Development 299 9 Current and Future Players 302 9.1 Trends in Corporate Strategy 305 9.2 Company Profiles 306 9.2.1 AbbVie 306 9.2.2 Pfizer 308 9.2.3 Amgen 311
9.2.4 Johnson & Johnson 314 9.2.5 Eli Lilly 316 9.2.6 Bristol-Myers Squibb 318 9.2.7 UCB 320 9.2.8 Roche 321 9.2.9 GlaxoSmithKline 323 9.2.10 Novartis 325 9.2.11 Sanofi 327 9.2.12 AstraZeneca- MedImmune 329 9.2.13 Astellas 331 9.2.14 Vertex 333 9.2.15 Daiichi Sankyo 335 About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com